Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. reduced its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 12.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 376,496 shares of the company's stock after selling 52,896 shares during the period. Janux Therapeutics comprises approximately 2.0% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s portfolio, making the stock its 17th biggest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned about 0.64% of Janux Therapeutics worth $10,165,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Russell Investments Group Ltd. raised its holdings in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after purchasing an additional 442 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Janux Therapeutics during the fourth quarter valued at about $59,000. GAMMA Investing LLC raised its stake in Janux Therapeutics by 1,574.0% in the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after buying an additional 1,574 shares in the last quarter. FNY Investment Advisers LLC lifted its holdings in Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after buying an additional 2,425 shares during the period. Finally, KBC Group NV bought a new stake in Janux Therapeutics during the 1st quarter valued at approximately $66,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the transaction, the insider owned 82,139 shares of the company's stock, valued at approximately $2,630,912.17. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 29.40% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial initiated coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $91.89.

Janux Therapeutics Stock Up 1.2%

Janux Therapeutics stock traded up $0.30 during mid-day trading on Tuesday, reaching $26.38. 655,503 shares of the company's stock traded hands, compared to its average volume of 878,998. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -19.40 and a beta of 2.86. The stock has a 50 day moving average of $24.62 and a two-hundred day moving average of $31.14. Janux Therapeutics, Inc. has a 12-month low of $22.48 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.